NOVELION THERAPEUTICS INC.
DelistedCIK 827809fmd_04VG1JMFWFG3EPGQZK0GKWGJWYManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Mar 31, 2019, 38 periods
| Line item | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 42 | 45 | 42 | – | – | – | – | – | 138 | 130 |
| Cost of revenue | 20 | 15 | 10 | – | – | 0 | 0 | 6 | 77 | 60 |
| Net interest income | – | – | – | – | – | 0 | 0 | (3) | (39) | (50) |
| Gross profit | 22 | 29 | 32 | – | – | – | – | – | 61 | 71 |
| Realized investment gains (losses) | – | – | – | – | – | 0 | 0 | (11) | – | – |
| Research and development | 29 | 11 | 23 | 25 | 19 | 14 | 10 | 15 | 49 | 39 |
| Selling, general and administrative | 18 | 14 | 17 | 15 | 7 | 18 | 16 | 30 | 96 | 80 |
| Total operating expenses | – | – | – | – | – | 4 | 23 | 44 | 148 | 121 |
| Operating income | (54) | (26) | (41) | (55) | (28) | (4) | (23) | (37) | (87) | (50) |
| Interest expense | 2 | – | – | – | – | – | – | – | – | – |
| Interest and investment income | 4 | 2 | 1 | 0 | – | – | – | – | – | – |
| Other non-operating income (expense) | 13 | 19 | 11 | 9 | 3 | (0) | 0 | (2) | (0) | (2) |
| Income before taxes | (42) | (7) | (30) | (46) | (25) | (4) | (23) | (52) | (126) | (107) |
| Income tax expense | (5) | 2 | 1 | (4) | 1 | (0) | 0 | 0 | 1 | 2 |
| Net income from continuing operations | (36) | (9) | (31) | (42) | (26) | (4) | (23) | (53) | (127) | (108) |
| Net income | 99 | (18) | (30) | 46 | (25) | (4) | (23) | (53) | (127) | (108) |